Immunovant (IMVT) Cash & Equivalents (2018 - 2026)

Immunovant (IMVT) has 9 years of Cash & Equivalents data on file, last reported at $902.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 26.35% year-over-year to $902.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $902.1 million (up 26.35% YoY) and the FY2026 annual result came in at $902.1 million, up 26.35% from the prior year.
• Cash & Equivalents declined to $902.1 million in Q1 2026, from $994.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $994.5 million in Q4 2025 to a low of $269.9 million in Q3 2023.
• A 5-year average of $541.2 million and a median of $493.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 45.77% — and 2025, when it soared 165.42%.
• Tracing IMVT's Cash & Equivalents over 5 years: stood at $432.6 million in 2022, then jumped by 59.71% to $690.9 million in 2023, then sank by 45.77% to $374.7 million in 2024, then surged by 165.42% to $994.5 million in 2025, then fell by 9.29% to $902.1 million in 2026.
• The last three Cash & Equivalents figures came in at $902.1 million (Q1 2026), $994.5 million (Q4 2025), and $521.9 million (Q3 2025), per Business Quant data.